ライフサイエンスコーパス: iodine-131

1 d cancer that was refractory to radioiodine (iodine-131).

2 ((125)I)-labeled FIAU was used in vitro and iodine 131 ((131)I)-labeled FIAU, in vivo.

3 estimate the maximum tolerated dose (MTD) of iodine 131 ((131)I)-tositumomab (anti-CD20 antibody) tha

4 n-Hodgkin's lymphoma (NHL) when labeled with iodine 131 ((131)I).

5 prednisone (CVP) followed by tositumomab and iodine-131 ((131)I) -tositumomab therapy were evaluated

6 d recombinant human TSH [rhTSH]) and the two iodine-131 ((131)I) activities (1.1 or 3.7 GBq).

7 ents exposed to radioactive iodines, chiefly iodine-131 ((131)I), after the 1986 Chornobyl (Ukrainian

8 ast one measurement of occult/minimal tumor (iodine 131[(131)I]-3F8 imaging, marrow immunocytology, o

9 of antibody labeled with escalating doses of iodine 131 (131I) was administered to patients with adva

10 proximately 740,000 Ci (2.73 x 10(16) Bq) of iodine 131 (131I) were released to the atmosphere from t

11 hnetium 99m (99mTc)-,iodine 123 (123I)-, and iodine 131 (131I)-labeled anti-CEA antibodies (all direc

12 ion tomography (PET), iodine-123- (123I) and iodine-131 (131I) -metaiodobenzylguanidine (MIBG), 111In

13 Preclinical studies suggest that iodine-131 (131I) -TM-601 may be an effective targeted t

14 sure to low or moderate doses of radioactive iodine-131 (131I) at a young age is a public health conc

15 0 monoclonal antibody (anti-B1) labeled with iodine-131 (131I) in 34 patients with B-cell lymphoma wh

16 trahematopoietic toxicity was conducted with iodine-131 (131I) labeled monoclonal antibody (MAb) CC49

17 by a single dose of the therapeutic isotope iodine-131 (131I) without evidence of recurrence up to 5

18 Iodine-131 anti-B1 antibody radioimmunotherapy for B-cel

19 patients treated with myeloablative doses of iodine-131-anti-CD20 antibody (anti-B1) and autologous s

20 ease, thyroid eye disease and treatment with iodine-131, antithyroid drug treatment, treatment of hyp

21 cancers that are refractory to radioiodine (iodine-131) are associated with a poor prognosis.

22 Iodine-131-FIBG is an analog of MIBG with prolonged bind

23 The use of radioactive iodine ((131)I) for the treatment of thyroid carcinoma h

24 ancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactory therapeuti

25 Patients with radioactive iodine ((131)I)-refractory locally advanced or metastati

26 A single, well-tolerated treatment with iodine (131)I tositumomab can, therefore, produce freque

27 py-relapsed/refractory patients treated with iodine (131)I tositumomab in a phase I/II single-center

28 Iodine-131 images were quantitated and used for pharmaco

29 High-dose iodine 131 is the treatment of choice in the United Stat

30 Iodine-131 is preferred by many investigators over other

31 Iodine-131-IUdR was used as a tracer for imaging and qua

32 Iodine-131-labeled anti-CD45 antibody has been added to

33 okinetics, and dosimetry of intraventricular iodine-131-labeled monoclonal antibody 3F8 (131I-3F8) ta

34 aging evaluation that included iodine-123 or iodine-131 metaiodobenzylguanidine (MIBG) scan, bone sca

35 Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) has bee

36 Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) provide

37 Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) selecti

38 2 to 4 months included computed tomography, iodine-131-metaiodobenzylguanidine (131)I-MIBG; through

39 prior therapy on response and toxicity after iodine-131-metaiodobenzylguanidine (131I-MIBG) treatment

40 odine-124 PET study indicated that a dose of iodine-131 of 2000 cGy or more could be delivered to the

41 and treatment (targeted radionuclide therapy/iodine-131) of melanoma.

42 al and the response rate among patients with iodine-131-refractory thyroid cancer.

43 a, attributable to the very large amounts of iodine 131 released, was first noticed in children with

44 timulate thyroid tissue so that radioiodine (iodine-131) scanning can be performed.

45 Iodine-131 scintigraphy for differentiated thyroid carci

46 ivity for fluorine 18 fluorodeoxyglucose and iodine 131 sodium iodide were generated.

47 ollicular thyroid cancer after postoperative iodine-131 therapy.

48 psed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day

49 HL were treated in a phase I trial combining iodine-131 tositumomab (ranging from 0.30 to 0.75 Gy tot

50 A follow-up phase II trial with iodine-131 tositumomab at the dose of 0.75 Gy TBD with B

51 t resulted in the regulatory approval of the iodine-131 tositumomab by the US Food and Drug Administr

52 ficacy, dosimetry methodology, and safety of iodine-131 tositumomab in patients with chemotherapy-rel

53 the five clinical trials of tositumomab and iodine-131 tositumomab in patients with relapsed or refr

54 Iodine-131 tositumomab produced a high overall response

55 The tositumomab and iodine-131 tositumomab therapeutic regimen produces high

56 ded toxicities apparent with the addition of iodine-131 tositumomab up to a dose of 0.75 Gy TBD to hi

57 apy plus an anti-CD20 antibody (rituximab or iodine-131 tositumomab) between 1998 and 2008.

58 Patients received a single course of iodine-131 tositumomab.

59 Iodine-131 uptake in the anterior mediastinum in patient

60 Postoperative iodine-131 was given to 85.4% of patients with papillary

61 Iodine-131 was measured in Potomac River water and sedim

62 essive thyroid cancer that was refractory to iodine-131, we randomly assigned 261 patients to receive